In a recent study posted to the medRxiv* preprint server, researchers evaluated the messenger ribonucleic acid (mRNA)-1273 vaccine effectiveness (VE) against severe acute respiratory syndrome ...
A large observational study using US healthcare claims and electronic health record data suggests that Moderna’s updated 2024 ...
In a recent study posted to the bioRxiv* preprint server, researchers assessed the impact of pre-existing immunity on messenger ribonucleic acid (mRNA) booster doses of BNT162b2 and mRNA-1273 vaccines ...
Higher vaccine efficacy was observed with mRNA-1283 vs mRNA-1273.222 in individuals aged 65 years and older. A phase 3 trial evaluating Moderna’s next-generation COVID-19 vaccine, mRNA-1283, met its ...
Current data reveals no significant differences in the antibody responses to the XBB.1 variant of SARS-CoV-2 between the BA.4/BA.5 and BA.1 vaccines. While the precise formulation of future vaccine ...
OBJECTIVESTo evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 variants and assess its effectiveness against the delta variant by time since vaccination. DESIGNTest negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback